Literature DB >> 17911647

IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.

Samiran Saha1, Smriti Mondal, Rajesh Ravindran, Swati Bhowmick, Dolanchampa Modak, Sudeshna Mallick, Mehboobar Rahman, Sourjya Kar, Ramaprasad Goswami, Subhasis Kamal Guha, Netai Pramanik, Bibhuti Saha, Nahid Ali.   

Abstract

Visceral leishmaniasis (VL) or kala-azar is known to be associated with a mixed Th1-Th2 response, and effective host defense requires the induction of IFN-gamma and IL-12. We address the role of the differential decline of IL-10 and TGF-beta in response to sodium antimony gluconate (SAG) and amphotericin B (AmB), the therapeutic success of SAG and AmB in Indian VL, and the significance of IL-10 and TGF-beta in the development and progression of post-kazla-azar dermal leishmaniasis (PKDL). In the active disease, PBMC from VL patients showed suppressed Ag-specific lymphoproliferation, IFN-gamma and IL-12 production, and elevation of IL-10 and TGF-beta. Cure corresponded with an elevation in IFN-gamma and IL-12 production and down-regulation of IL-10 and TGF-beta. Both CD4(+) and CD8(+) T cells were involved in IFN-gamma and IL-10 production. Interestingly, the retention and maintenance of residual IL-10 and TGF-beta in some SAG-treated individuals and the elevation of IL-10 and TGF-beta in PKDL, a sequel to kala-azar, probably reflects the role of these cytokines in reactivation of the disease in the form of PKDL. Contrastingly, AmB treatment of VL resulted in negligible TGF-beta levels and absolute elimination of IL-10, reflecting the better therapeutic activity of AmB and its probable role in the recent decline in PKDL occurrences in India. Moreover, elucidation of immune responses in Indian PKDL patients revealed a spectral pattern of disease progression where disease severity could be correlated inversely with lymphoproliferation and directly with TGF-beta, IL-10, and Ab production. In addition, the enhancement of CD4(+)CD25(+) T cells in active VL, their decline at cure, and reactivation in PKDL suggest their probable immunosuppressive role in these disease forms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911647     DOI: 10.4049/jimmunol.179.8.5592

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  74 in total

1.  Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride.

Authors:  Chandeshwar P Thakur; A Kumar; Dipendra K Mitra; Ambak Roy; Arun Kumar Sinha; Alok Ranjan
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

2.  Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood.

Authors:  Om Prakash Singh; Kamlesh Gidwani; Rajiv Kumar; Susanne Nylén; Stephen L Jones; Marleen Boelaert; David Sacks; Shyam Sundar
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

3.  Is the IL-10 -819 polymorphism associated with visceral leishmaniasis?

Authors:  Mehrdad Hajilooi; Kosro Sardarian; Maryam Dadmanesh; Mohamad Matini; Pegah Lotfi; Ahad Bazmani; Mohammad Amin Tabatabaiefar; Mohammad Kazemi Arababadi; Mohammad Momeni
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

4.  CD8 T cell exhaustion in human visceral leishmaniasis.

Authors:  Shalini Gautam; Rajiv Kumar; Neetu Singh; Abhishek Kumar Singh; Madhukar Rai; David Sacks; Shyam Sundar; Susanne Nylén
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

5.  A chemical inhibitor of heat shock protein 78 (HSP78) from Leishmania donovani represents a potential antileishmanial drug candidate.

Authors:  Sonali Das; Anindyajit Banerjee; Mohd Kamran; Sarfaraz Ahmad Ejazi; Mohammad Asad; Nahid Ali; Saikat Chakrabarti
Journal:  J Biol Chem       Date:  2020-05-29       Impact factor: 5.157

6.  Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3+ CD4 cells in blood or spleen.

Authors:  R Maurya; R Kumar; V K Prajapati; K D Manandhar; D Sacks; S Sundar; S Nylén
Journal:  Parasite Immunol       Date:  2010-07       Impact factor: 2.280

7.  Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol.

Authors:  June Ghosh; Shantanabha Das; Rajan Guha; Debopam Ghosh; Kshudiram Naskar; Anjan Das; Syamal Roy
Journal:  J Lipid Res       Date:  2012-10-10       Impact factor: 5.922

8.  TGF-beta and mesenchymal hepatic involvement after visceral leishmaniasis.

Authors:  Maria Irma Seixas Duarte; Heitor Franco de Andrade; Cleusa Fumica Hirata Takamura; Antonio Sesso; Felipe Francisco Tuon
Journal:  Parasitol Res       Date:  2008-12-05       Impact factor: 2.289

9.  Immunological perspectives of leishmaniasis.

Authors:  Susanne Nylén; Shalini Gautam
Journal:  J Glob Infect Dis       Date:  2010-05

Review 10.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.